Hepatitis B Trial, Recruiting NCT06803368 Sponsor: Beijing Municipal Administration of Hospitals Condition: Hepatitis B
Back to Hepatitis B

Hepatitis B Trial, Recruiting

NCT06803368
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 18 and 65 years old
  • You are any gender
  • You have been diagnosed with chronic Hepatitis B (a long-term liver infection caused by the Hepatitis B virus), based on 2019 medical guidelines
  • Your Hepatitis B was treated with interferon, and that treatment caused the surface protein of the virus (HBsAg) to disappear, another viral marker (HBeAg) to become undetectable, and the virus levels in your blood to drop below what tests can measure — and you have since stopped interferon treatment
  • You are willing and able to sign a consent form agreeing to take part in the trial

Who may not be able to join:

  • You also have another hepatitis virus infection, such as Hepatitis C (HCV) or Hepatitis D (HDV)
  • You have a liver disease caused by your immune system attacking your own body (autoimmune liver disease)
  • You have HIV infection
  • You have a long history of heavy alcohol use and/or have taken medications or substances known to damage the liver
  • You have a mental illness
  • You have signs of liver tumors (liver cancer), or a specific blood marker called AFP is above a certain level (confirm with trial site)
  • Your liver disease has reached an advanced stage where the liver can no longer function properly (decompensated cirrhosis)
  • You have serious health conditions affecting your heart, brain, lungs, kidneys, or other major organs that would prevent you from attending regular long-term follow-up appointments

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Minghui Li, Beijing Ditan Hospital

Phone: 13581975577

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Beijing Municipal Administration of Hospitals
Registry
ClinicalTrials.gov
Start date
1 November 2024
Est. completion
30 October 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Sustained response rate and relapse rate by virological and serological indicators

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov